ASMB news

Latest 2 stories · newest May 26, 2026

ASMB

Assembly Biosciences prices underwritten offering of common stock and pre-funded warrants

Assembly Biosciences launched an underwritten public offering of 3.36 million shares of common stock and pre-funded warrants to purchase 415,000 shares, with Guggenheim Securities and UBS as lead underwriters. The offering provides capital for the biotech company's operations and development program…

Offering May 26, 2026 sentiment 0.00 SEC filing ↗

ASMB

Assembly Biosciences expands ABI-6250 into cholestatic liver diseases with Phase 2 planned for Q1 2027

Assembly Biosciences announced expansion of its oral NTCP inhibitor ABI-6250 into primary biliary cholangitis and primary sclerosing cholangitis, with a Phase 2 study anticipated to initiate in Q1 2027. The expansion addresses significant unmet medical needs in cholestatic liver diseases and broaden…

Regulatory May 22, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ASMB feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ASMB/newsSTART FREE